enGene Holdings Inc. 8-K

What Happened
enGene Holdings Inc. announced on January 20, 2026 that it entered into a Second Amendment to its Amended and Restated Loan and Security Agreement. The original loan agreement was dated December 22, 2023 and had previously been amended on December 18, 2024. The amendment involves the company and its subsidiaries as borrowers, with Hercules Capital, Inc. acting as agent and lender alongside other participating banks and financial institutions. The company furnished a press release describing the amendment as Exhibit 99.1 to its Form 8-K filed January 21, 2026 (signed by CFO Ryan Daws).

Key Details

• Agreement: Second Amendment to the Amended and Restated Loan and Security Agreement (originally dated Dec 22, 2023).
• Prior amendment: First Amendment dated Dec 18, 2024.
• Parties: enGene Holdings Inc. and its subsidiaries (borrowers) and Hercules Capital, Inc. (agent/lender) plus other lenders.
• Filing: Form 8-K filed Jan 21, 2026; press release dated Jan 20, 2026 furnished as Exhibit 99.1.

Why It Matters
Changes to a company’s loan agreements can affect liquidity, debt covenants, repayment schedules or borrowing capacity. The Form 8-K notifies investors that financing terms have been modified, but does not detail the specific economic or covenant changes in the amendment itself — investors should review the press release (Exhibit 99.1) and await any follow-up filings for full terms. This is a material financing update relevant to enGene’s capital structure and near-term financial flexibility.